• R G Langley, K Papp, M Gooderham, L Zhang, C Mallinckrodt, N Agada, A Blauvelt, P Foley, P Polzer, and of the IXORA-P Investigators.
• Dalhousie University, Halifax, NS, Canada.
• Br. J. Dermatol. 2018 Jun 1; 178 (6): 1315-1323.

BackgroundIxekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter.ObjectiveTo evaluate continuous Q2W dosing over 52 weeks.MethodsIn this phase III, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2 : 1 : 1 ratio to continuous Q2W (n = 611), continuous Q4W (n = 310) or dose adjustment per protocol (Q4W/Q2W, n = 306), each with a 160-mg starting dose. Dose adjustment was determined by predefined criteria to which investigators were blinded; 72 (23?5%) patients in the Q4W/Q2W group adjusted dose. Efficacy outcomes were evaluated using logistic regression.ResultsCo-primary end points were met at week 52: Psoriasis Area and Severity Index 75 responses for Q2W and Q4W dose groups were 85·9% and 79·0%, respectively (P = 0·006), and static patient global assessment 0/1 responses for Q2W and Q4W dose groups were 78·6% and 70·6%, respectively (P = 0·005). Treatment-emergent and serious adverse events were comparable across dose groups.ConclusionsIxekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

18 keywords...

hide…